Does Cosentyx Affect Vaccine Response?
Cosentyx (secukinumab), an IL-17 inhibitor for psoriasis, psoriatic arthritis, and ankylosing spondylitis, suppresses parts of the immune system. This can weaken responses to some vaccines, especially live ones, but data supports caution rather than outright bans around vaccination timing.[1]
Can You Take Cosentyx Right After Getting Vaccinated?
Clinical guidelines and the prescribing information advise against starting or resuming Cosentyx immediately after vaccination. For inactivated vaccines like COVID-19 mRNA shots (Pfizer, Moderna) or flu vaccines, experts recommend waiting 2-4 weeks post-vaccination before initiating biologic therapy like Cosentyx to allow peak immune response development. This minimizes interference with antibody production.[2][3]
No large-scale studies directly test "right after" timing, but real-world data from psoriasis patients shows biologics like secukinumab reduce vaccine efficacy if started too soon. The American College of Rheumatology suggests holding immunosuppressants for 1-2 weeks pre- and post-vaccination when possible.[4]
What About Live Vaccines?
Avoid live vaccines (e.g., MMR, varicella, oral polio, yellow fever) entirely while on Cosentyx or within several weeks after stopping it. The drug's label prohibits live vaccines due to infection risk.[2]
Timing Recommendations for Common Vaccines
| Vaccine Type | Hold Cosentyx Before? | Start/Resume After? |
|--------------|-----------------------|---------------------|
| Inactivated (COVID-19, flu, pneumococcal) | 1-2 weeks if possible | 2-4 weeks post-vaccination |
| Live attenuated | Avoid completely | N/A – wait 4+ weeks after stopping Cosentyx |
| Subunit/recombinant (Shingrix) | 1 week ideal | 2 weeks post-dose |
These align with EULAR and GRAPPPA guidelines for rheumatic diseases.[5]
Patient Experiences and Risks
Patients report adequate COVID-19 protection if vaccinated before starting Cosentyx, but breakthrough infections rise with concurrent use. A 2023 study of 1,300+ biologic users found secukinumab patients had 20-30% lower antibody levels post-vaccination compared to non-immunosuppressed groups.[6] Risks include poorer long-term immunity and higher infection odds – discuss with your rheumatologist or dermatologist for personalized antibody testing.
Alternatives During Vaccination Periods
Short-term switches to non-biologic options like methotrexate (lower vaccine impact) or topicals may bridge gaps. For urgent needs, some continue Cosentyx but prioritize vaccination first.[4]
Sources
[1] Cosentyx Prescribing Information, Novartis (https://www.cosentyx.com)
[2] FDA Label for Secukinumab (https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125504s042lbl.pdf)
[3] CDC Immunosuppressants and Vaccines (https://www.cdc.gov/vaccines/adults/rec-vac/health-conditions/immunosuppressants.html)
[4] American College of Rheumatology COVID-19 Guidance (https://rheumatology.org/covid-19-vaccine-clinical-guidance)
[5] EULAR Recommendations for Vaccination in Rheumatic Diseases (https://ard.bmj.com/content/82/3/335)
[6] Annals of Rheumatic Diseases Study on Biologics and COVID Vaccines (https://ard.bmj.com/content/82/5/647)